Virginia Retirement Systems ET AL bought a new stake in Chimerix Inc. (NASDAQ:CMRX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,300 shares of the biopharmaceutical company’s stock, valued at approximately $103,000. Virginia Retirement Systems ET AL owned approximately 0.06% of Chimerix at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. boosted its stake in Chimerix by 5.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,256,191 shares of the biopharmaceutical company’s stock valued at $16,640,000 after buying an additional 156,969 shares in the last quarter. A.R.T. Advisors LLC boosted its stake in Chimerix by 3,008.7% in the first quarter. A.R.T. Advisors LLC now owns 866,059 shares of the biopharmaceutical company’s stock valued at $4,425,000 after buying an additional 838,200 shares in the last quarter. Opaleye Management Inc. bought a new stake in Chimerix during the first quarter valued at approximately $3,449,000. Geode Capital Management LLC boosted its stake in Chimerix by 1.0% in the first quarter. Geode Capital Management LLC now owns 286,085 shares of the biopharmaceutical company’s stock valued at $1,461,000 after buying an additional 2,755 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Chimerix by 103.2% in the second quarter. Dimensional Fund Advisors LP now owns 153,408 shares of the biopharmaceutical company’s stock valued at $603,000 after buying an additional 77,900 shares in the last quarter. 66.12% of the stock is currently owned by institutional investors and hedge funds.
Chimerix Inc. (NASDAQ:CMRX) opened at 4.72 on Thursday. The company’s market cap is $218.13 million. Chimerix Inc. has a 12 month low of $3.49 and a 12 month high of $43.37. The company’s 50-day moving average is $5.16 and its 200-day moving average is $4.79.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.12. Chimerix had a negative return on equity of 34.75% and a negative net margin of 1,356.50%. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.98 million. On average, equities research analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current year.
A number of analysts have issued reports on CMRX shares. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Zacks Investment Research cut shares of Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $7.00 target price on shares of Chimerix in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $12.38.
In other Chimerix news, insider M Michelle Berrey purchased 22,417 shares of the company’s stock in a transaction on Monday, August 29th. The shares were purchased at an average cost of $4.47 per share, with a total value of $100,203.99. Following the completion of the purchase, the insider now owns 281,238 shares in the company, valued at $1,257,133.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John M. Leonard sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $5.03, for a total value of $25,150.00. The disclosure for this sale can be found here. 10.50% of the stock is owned by corporate insiders.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.